The following adverse effects were reported in patients receiving semaglutide injection or oral tablets across all clinical trials and at incidences higher than with placebo: nausea (11% to 44%), vomiting (5% to 24%), diarrhea (8.5% to 30%), abdominal pain (5.7% to 20%), abdominal distention (2% to 7%), constipation (3.1% to 24%), dyspepsia (0.6% to 9%), decreased appetite (6% to 9%), eructation (0.6% to 7%), flatulence (0.4% to 6%), gastroesophageal reflux disease (1.5% to 5%), gastroenteritis (4% to 6%), and gastritis (0.4% to 4%)
This product is not a drug, food, or cosmetic and is not intended for human or veterinary use, diagnosis, or therapeutic application
Research profiles its selectivity for NNMT over other methyltransferases and establishes structure-activity relationships
This helps in the growth and development of bones as well as reduces the risk of bone disorders like osteoporosis
Ask the injector if you can downsize the needle gauge